PMC:6723065 / 34140-34697 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6723065","sourcedb":"PMC","sourceid":"6723065","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6723065","text":"AchEI (donepezil 5–10 mg daily, galantamine 4–8 mg twice a day, rivastigmine 1.5 mg twice a day up to 6 mg bid) can improve cognition in PD-MCI and in PDD patients [118]. Rivastigmine efficacy seems higher, especially in PDD patients, as compared to the other two drugs [60,119]. However, although AchEI does not seem to significantly increase the rate of falls in these patients, a worsening of tremor may appear. Donepezil seems to show less adverse effects, as compared to Rivastigmine, and could be employed in patients with more prominent tremor [120].","tracks":[{"project":"2_test","denotations":[{"id":"31434341-22419314-7278324","span":{"begin":165,"end":168},"obj":"22419314"},{"id":"31434341-22998158-7278325","span":{"begin":271,"end":273},"obj":"22998158"},{"id":"31434341-25914281-7278326","span":{"begin":274,"end":277},"obj":"25914281"},{"id":"31434341-25224676-7278327","span":{"begin":552,"end":555},"obj":"25224676"}],"attributes":[{"subj":"31434341-22419314-7278324","pred":"source","obj":"2_test"},{"subj":"31434341-22998158-7278325","pred":"source","obj":"2_test"},{"subj":"31434341-25914281-7278326","pred":"source","obj":"2_test"},{"subj":"31434341-25224676-7278327","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#93ec9c","default":true}]}]}}